Exscientia uses AI technologies in Sanofi drug discovery deal; later exercises option on fibrosis target
Exscientia Ltd. will use its artificial intelligence (AI)-based drug design technology to discover new bispecific small-molecule metabolic disease therapies for Sanofi.
- Artificial Intelligence
- Drug Discovery Tools
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.